About Anadys Pharmaceuticals (NASDAQ:ANDS)
Anadys Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing medicines for the treatment of hepatitis C. The Company is focusing on the development of ANA598, a direct-acting antiviral (DAA) for the treatment of hepatitis C. It also focuses to resume the clinical development of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway for the treatment of hepatitis C. In January 2011, the Company initiated a Phase IIb clinical study of ANA598 in combination with SOC for the treatment of hepatitis C. In the Phase IIb study, approximately 200 chronically infected genotype 1 hepatitis C patients are to receive ANA598 200 mg bid in combination with standard of care (SOC), with a loading dose of 800 mg ANA598 bid on day one. In addition, approximately 66 chronically infected genotype 1 hepatitis C patients are to receive placebo added to SOC.
Industry, Sector and Symbol
Industry Bio Therapeutic Drugs
Trailing P/E RatioN/A
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Return on EquityN/A
Return on AssetsN/A
Anadys Pharmaceuticals (NASDAQ:ANDS) Frequently Asked Questions
What is Anadys Pharmaceuticals' stock symbol?
Anadys Pharmaceuticals trades on the NASDAQ under the ticker symbol "ANDS."
Who are some of Anadys Pharmaceuticals' key competitors?
Some companies that are related to Anadys Pharmaceuticals include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Medivation (MDVN), Bioverativ (BIVV), bluebird bio (BLUE), Kite Pharma (KITE), Juno Therapeutics (JUNO), Exelixis (EXEL), Neurocrine Biosciences (NBIX), Beigene (BGNE), Shire-Nps Pharmaceuticals (NPSP), Agios Pharmaceuticals (AGIO), AveXis (AVXS), Sarepta Therapeutics (SRPT), GW Pharmaceuticals PLC- (GWPH), Array BioPharma (ARRY) and Auspex Pharmaceuticals (ASPX).
How do I buy Anadys Pharmaceuticals stock?
Shares of Anadys Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How can I contact Anadys Pharmaceuticals?
Anadys Pharmaceuticals' mailing address is Suite 200, 5871 Oberlin Drive, SAN DIEGO, CA 92121, United States. The biopharmaceutical company can be reached via phone at +1-858-5303600.
MarketBeat Community Rating for Anadys Pharmaceuticals (ANDS)MarketBeat's community ratings are surveys of what our community members think about Anadys Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Anadys Pharmaceuticals (NASDAQ:ANDS) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Anadys Pharmaceuticals (NASDAQ:ANDS) Earnings History and Estimates Chart
Anadys Pharmaceuticals (NASDAQ ANDS) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Anadys Pharmaceuticals (NASDAQ:ANDS) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Anadys Pharmaceuticals (NASDAQ:ANDS)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Anadys Pharmaceuticals (NASDAQ ANDS)
No insider trades for this company have been tracked by MarketBeat.com
Anadys Pharmaceuticals (NASDAQ ANDS) News Headlines
No headlines for this company have been tracked by MarketBeat.com
Anadys Pharmaceuticals (NASDAQ:ANDS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Anadys Pharmaceuticals (NASDAQ:ANDS) Income Statement, Balance Sheet and Cash Flow Statement
Anadys Pharmaceuticals (NASDAQ ANDS) Stock Chart for Saturday, February, 17, 2018